Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®

Primary Purpose:

* To compare the efficacy in treating dry eye syndrome in contact lens wearers or computer users of Tears Again® versus Opticol® versus Optive®

Secondary Purpose:

* Subjective evaluation of symptomatology * Evaluation of preference in different kind of administration - spray versus monodoses versus multi-doses

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Syndrome Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Serviço de Oftalmologia, Hospital de São Sebastião

Santa Maria da Feira, 4520-211, Portugal

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Informed Consent signed
Age >18 years and < 55 years
Daily wearer of soft contact lens and/or daily (> 4 hours/day) computer user

Exclusion criteria

Dry eye Syndrome other than of evaporative etiology, according to DEWS
Ocular or systemic disease that can affect the normal tear film
Pregnancy or pregnancy risk (no contraceptive method), lactation

Sponsors and collaborators

Lead sponsor

Hospital de Sao Sebastiao

Other

Registry information

Official study title

Efficacy Comparative Study Between Tears Again®, o Opticol® e o Optive® in Clinical and Symptomatology Treatment of Dry Eye Syndrome in Contact Lens Wearers and/or Computers Users

Important dates

First posted: May 5, 2009
Registry last updated: May 5, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed